TT International Asset Management LTD Sells 38,000 Shares of Denali Therapeutics Inc. $DNLI

TT International Asset Management LTD reduced its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 58.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 27,000 shares of the company’s stock after selling 38,000 shares during the period. TT International Asset Management LTD’s holdings in Denali Therapeutics were worth $446,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Headlands Technologies LLC bought a new position in Denali Therapeutics during the 2nd quarter valued at about $26,000. Johnson Financial Group Inc. bought a new position in Denali Therapeutics during the 3rd quarter valued at about $29,000. State of Wyoming bought a new position in Denali Therapeutics during the 2nd quarter valued at about $29,000. Quarry LP bought a new position in Denali Therapeutics during the 3rd quarter valued at about $64,000. Finally, Intrust Bank NA bought a new position in Denali Therapeutics during the 3rd quarter valued at about $154,000. 92.92% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Denali Therapeutics in a research note on Wednesday, January 21st. Stifel Nicolaus boosted their target price on shares of Denali Therapeutics from $34.00 to $41.00 and gave the stock a “buy” rating in a research note on Thursday, March 26th. UBS Group assumed coverage on shares of Denali Therapeutics in a research note on Wednesday, January 7th. They issued a “buy” rating for the company. Robert W. Baird boosted their target price on shares of Denali Therapeutics from $32.00 to $34.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 7th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $40.00 target price on shares of Denali Therapeutics in a research note on Monday, March 2nd. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $35.00.

View Our Latest Report on DNLI

Trending Headlines about Denali Therapeutics

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: HC Wainwright slightly raised near‑term EPS estimates (Q3 and Q4 2026) and nudged FY2026 marginally better, and it keeps a “Buy” rating with a $42 price target — a signal of analyst confidence in the pipeline despite losses. HC Wainwright note
• Positive Sentiment: Robert W. Baird raised its price target to $34, which supports upside expectations relative to the current share level and can attract investors looking for re-rating opportunities. Robert W. Baird Raises Price Target
• Neutral Sentiment: A Globe and Mail piece offers broader analyst commentary on DNLI alongside peers — useful context but not new company‑specific catalysts. Analysts Offer Insights (Globe and Mail)
• Neutral Sentiment: Reported short‑interest data appears to contain errors (shows 0 shares / NaN change) and is not meaningful for gauging current short pressure. Investors should treat the short‑interest read as unreliable until corrected.
• Negative Sentiment: Despite the near‑term tweaks, HC Wainwright substantially lowered EPS forecasts for FY2027–FY2030 (large downward revisions to long‑range profitability), which increases uncertainty about the timing of profitability and may weigh on sentiment for a development‑stage biotech. HC Wainwright note

Denali Therapeutics Trading Down 0.3%

DNLI opened at $19.23 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.16 and a quick ratio of 9.16. The company has a market cap of $3.05 billion, a price-to-earnings ratio of -6.47 and a beta of 1.10. The firm has a 50 day simple moving average of $20.31 and a 200 day simple moving average of $18.27. Denali Therapeutics Inc. has a fifty-two week low of $12.02 and a fifty-two week high of $23.77.

Denali Therapeutics (NASDAQ:DNLI – Get Free Report) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.02. During the same quarter in the prior year, the company earned ($0.67) EPS. On average, sell-side analysts anticipate that Denali Therapeutics Inc. will post -2.71 earnings per share for the current year.

Denali Therapeutics Company Profile

(Free Report)

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.

Featured Articles

• Five stocks we like better than Denali Therapeutics

Want to see what other hedge funds are holding DNLI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report).